Canadian Cancer Society logo

Kidney cancer

You are here: 

If kidney cancer spreads

Cancer cells can spread from the kidney to other parts of the body and develop into a new tumour. The new tumour is called a metastasis, or secondary tumour. If more than one tumour develops in another part of the body, they are called metastases.

Understanding how a type of cancer usually grows and spreads helps your healthcare team plan your treatment and future care. If kidney cancer spreads, it is most likely to spread throughout the kidney. Then it can spread through the fibrous tissue covering the kidney (called the renal capsule) and into the fat around the kidney. Kidney cancer can then spread through the fibrous tissue covering the fat around the kidney (called Gerota’s fascia).

If kidney cancer spreads outside of the kidney, it can spread to the following:

  • lymph nodes around the kidney
  • the main vein in the kidney (called the renal vein)
  • the large vein in the abdomen leading to the heart (called the vena cava)
  • adrenal glands
  • the other kidney
  • muscles in the pelvis and abdomen, such as the diaphragmdiaphragmThe thin muscle below the lungs and heart that separates the chest cavity from the abdomen.
  • lungs
  • liver
  • bones
  • brain

Very rarely, kidney metastasis can disappear without any treatment. This is called a spontaneous regression. But the metastasis usually comes back, or recurs, where it disappeared. It often comes back within a few months.

Spontaneous regression sometimes happens after doctors remove a kidney with advanced cancer to help relieve pain or bleeding. This doesn’t happen very often, so surgery is not done to try to bring about a spontaneous regression.

Stories

Tyler Cook This research saved my life and my sister’s life. Without it, stomach cancer would have wiped out most of our family.

Read Tyler's story

Clinical trial discovery improves quality of life

Illustration of test tubes

A clinical trial led by the Society’s NCIC Clinical Trials group found that men with prostate cancer who are treated with intermittent courses of hormone therapy live as long as those receiving continuous therapy.

Learn more